SciELO - Scientific Electronic Library Online

 
vol.80 número3Isquemia miocárdica sin lesiones coronarias obstructivas: MINOCA-INOCA: Revisión para la toma de decisiones GREECO (Grupo de Estudio de Enfermedades Coronarias)Mielitis longitudinal extensa de presentación muy tardía: Una entidad del espectro de la neuromielitis óptica índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Medicina (Buenos Aires)

versión impresa ISSN 0025-7680versión On-line ISSN 1669-9106

Resumen

ZAIDEL, Ezequiel J et al. Hidroxicloroquina: Mensajes desde la cardiología en tiempos de pandemia por Coronavirus. Medicina (B. Aires) [online]. 2020, vol.80, n.3, pp.271-274. ISSN 0025-7680.

Due to the coronavirus disease 2019 (COVID-19) pandemic, a wide number of compounds are under scrutiny regarding their antiviral activity, one of them being hydroxychloroquine. Cardiac aspects of the use of chloroquine and hydroxychloroquine are reviewed in this manuscript. A non-systematic review of the medical literature was performed. Information about their safety and efficacy as antimalarials, antivirals, as well as in the long-term treatment of rheumatic diseases was collected. We found an anti-inflammatory effect with reduction of long-term cardiovascular events, a very infrequent heart disease due to a lysosomal effect of the drug, and at the hemodynamic level hypotension, tachycardia, and QT interval prolongation, exacerbated when combined with azithromycin. However, the rate of adverse cardiac events of hydroxychloroquine (and chloroquine) was low.

Palabras clave : Coronavirus; COVID-19; Pandemic; Hydroxychloroquine; Chloroquine; Long QT syndrome; Cardiovascular system; Azithromycin.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons